Extended use for Roche drugs

Roche’s cancer drug MabThera has been recommended as a maintenance drug for NHS patients with follicular non-Hodgkin’s lymphoma by the National Institute for Health and Clinical Excellence (NICE). NICE said it could postpone the spread and growth of cancer by up to four years.